294 related articles for article (PubMed ID: 9405613)
21. Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization.
Mateu MG; Fersht AR
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3595-9. PubMed ID: 10097082
[TBL] [Abstract][Full Text] [Related]
22. The effect of R249S carcinogenic and H168R-R249S suppressor mutations on p53-DNA interaction, a multi scale computational study.
Rauf SM; Ismael M; Sahu KK; Suzuki A; Koyama M; Tsuboi H; Hatakeyama N; Endou A; Takaba H; Del Carpio CA; Kubo M; Miyamoto A
Comput Biol Med; 2010 May; 40(5):498-508. PubMed ID: 20403587
[TBL] [Abstract][Full Text] [Related]
23. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug.
Boeckler FM; Joerger AC; Jaggi G; Rutherford TJ; Veprintsev DB; Fersht AR
Proc Natl Acad Sci U S A; 2008 Jul; 105(30):10360-5. PubMed ID: 18650397
[TBL] [Abstract][Full Text] [Related]
24. R248Q mutation--Beyond p53-DNA binding.
Ng JW; Lama D; Lukman S; Lane DP; Verma CS; Sim AY
Proteins; 2015 Dec; 83(12):2240-50. PubMed ID: 26442703
[TBL] [Abstract][Full Text] [Related]
25. Solvent-exposed residues located in the beta-sheet modulate the stability of the tetramerization domain of p53--a structural and combinatorial approach.
Mora P; Carbajo RJ; Pineda-Lucena A; Sánchez del Pino MM; Pérez-Payá E
Proteins; 2008 Jun; 71(4):1670-85. PubMed ID: 18076077
[TBL] [Abstract][Full Text] [Related]
26. High-resolution structure of the p53 core domain: implications for binding small-molecule stabilizing compounds.
Ho WC; Luo C; Zhao K; Chai X; Fitzgerald MX; Marmorstein R
Acta Crystallogr D Biol Crystallogr; 2006 Dec; 62(Pt 12):1484-93. PubMed ID: 17139084
[TBL] [Abstract][Full Text] [Related]
27. Effects of stability on the biological function of p53.
Khoo KH; Mayer S; Fersht AR
J Biol Chem; 2009 Nov; 284(45):30974-80. PubMed ID: 19700401
[TBL] [Abstract][Full Text] [Related]
28. Investigating DNA Binding and Conformational Variation in Temperature Sensitive p53 Cancer Mutants Using QM-MM Simulations.
Koulgi S; Achalere A; Sonavane U; Joshi R
PLoS One; 2015; 10(11):e0143065. PubMed ID: 26579714
[TBL] [Abstract][Full Text] [Related]
29. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain.
Mateu MG; Fersht AR
EMBO J; 1998 May; 17(10):2748-58. PubMed ID: 9582268
[TBL] [Abstract][Full Text] [Related]
30. Adaptive evolution of p53 thermodynamic stability.
Khoo KH; Andreeva A; Fersht AR
J Mol Biol; 2009 Oct; 393(1):161-75. PubMed ID: 19683006
[TBL] [Abstract][Full Text] [Related]
31. Oxidation of methionine residue at hydrophobic core destabilizes p53 tetrameric structure.
Nomura T; Kamada R; Ito I; Chuman Y; Shimohigashi Y; Sakaguchi K
Biopolymers; 2009 Jan; 91(1):78-84. PubMed ID: 18781628
[TBL] [Abstract][Full Text] [Related]
32. Factors governing loss and rescue of DNA binding upon single and double mutations in the p53 core domain.
Wright JD; Noskov SY; Lim C
Nucleic Acids Res; 2002 Apr; 30(7):1563-74. PubMed ID: 11917017
[TBL] [Abstract][Full Text] [Related]
33. Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding.
Kaar JL; Basse N; Joerger AC; Stephens E; Rutherford TJ; Fersht AR
Protein Sci; 2010 Dec; 19(12):2267-78. PubMed ID: 20878668
[TBL] [Abstract][Full Text] [Related]
34. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain.
Butler JS; Loh SN
Biochemistry; 2003 Mar; 42(8):2396-403. PubMed ID: 12600206
[TBL] [Abstract][Full Text] [Related]
35. Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study.
Kamaraj B; Bogaerts A
PLoS One; 2015; 10(8):e0134638. PubMed ID: 26244575
[TBL] [Abstract][Full Text] [Related]
36. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells.
Cao Y; Gao Q; Wazer DE; Band V
Cancer Res; 1997 Dec; 57(24):5584-9. PubMed ID: 9407971
[TBL] [Abstract][Full Text] [Related]
37. p53 induces distinct epigenetic states at its direct target promoters.
Vrba L; Junk DJ; Novak P; Futscher BW
BMC Genomics; 2008 Oct; 9():486. PubMed ID: 18922183
[TBL] [Abstract][Full Text] [Related]
38. Mechanism and thermodynamics of guanidinium chloride-induced denaturation of ALS-associated mutant Cu,Zn superoxide dismutases.
Rumfeldt JA; Stathopulos PB; Chakrabarrty A; Lepock JR; Meiering EM
J Mol Biol; 2006 Jan; 355(1):106-23. PubMed ID: 16307756
[TBL] [Abstract][Full Text] [Related]
39. Elucidating the Mechanisms of R248Q Mutation-Enhanced p53 Aggregation and Its Inhibition by Resveratrol.
Liu Q; Li L; Yu Y; Wei G
J Phys Chem B; 2023 Sep; 127(36):7708-7720. PubMed ID: 37665658
[TBL] [Abstract][Full Text] [Related]
40. In the quest for stable rescuing mutants of p53: computational mutagenesis of flexible loop L1.
Pan Y; Ma B; Venkataraghavan RB; Levine AJ; Nussinov R
Biochemistry; 2005 Feb; 44(5):1423-32. PubMed ID: 15683227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
